SecBot SecBot
PRESS-RELEASE ·Filed Mar 31, 2026

INKT

MiNK Therapeutics
MIXED
Impact 5/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

While fundamentals show increased losses, the substantial cash improvement and non-dilutive funding reduce near-term dilution risk. Multiple 2026 clinical catalysts (ARDS, GVHD, IPF) could drive value inflection; traders should monitor trial initiations and data readouts as key triggers.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$10.53
T+0 close · Mar 31, 2026 · via day close
Latest settled
+10.54%
T+60 · $11.64
Vs SPY
−1.84%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 31 $10.53entry
  2. T+1 · 8mo ago +0.38%α −0.37% · $10.57
  3. T+5 · 7mo ago +5.89%α +1.94% · $11.15
  4. T+20 · 7mo ago +4.61%α −4.82% · $11.02
  5. T+60 · 5mo ago +10.54%α −1.84% · $11.64
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MiNK Therapeutics reported financial results for Q4 and full year 2025, highlighting a net loss increase to $12.5M but improved cash position of $13.4M, supported by non-dilutive funding and a recent $3M raise. The company emphasized pipeline progress, including upcoming Phase 2 trials in ARDS and GVHD, with multiple clinical catalysts expected in 2026.

Key Financial Metrics

EPS
$-2.93
Deal Value
$1.1M

Key Facts

  • Net loss for FY 2025 was $12.5 million, up from $10.8 million in 2024.
  • Cash and cash equivalents totaled $13.36 million as of December 31, 2025, up from $4.58 million in 2024.
  • Raised additional $3.0 million post-year-end via at-the-market offering, extending cash runway into 2026.
  • Phase 2 trial for agenT-797 in ARDS to initiate in 1H 2026, with early data expected by year-end.
  • GVHD program fully funded by NIH grant and philanthropic award, with first dosing expected May 2026.
  • C-Further Consortium collaboration provides up to $1.1 million in non-dilutive funding plus revenue share for PRAME-TCR iNKT program.

Financial Impact

Net loss increased 15.7% YoY to $12.5M; cash position improved by $8.78M; $3M raised post-period; $1.1M non-dilutive funding secured.

cashnet_lossdilutionfunding

Risk Factors

  • Continued net losses may pressure valuation if clinical milestones are delayed.
  • Reliance on external funding for GVHD program creates execution risk if trial timelines slip.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3265350

Track record

21 reports on INKT

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.93% at T+20 after the May 15, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $9.53 Now $9.35 −1.89% settles Dec 11
  2. Nov 11, 20265d ago Press Release Neutral 4/10 Entry $10.22 Now $9.35 −8.55% settles Dec 10
  3. Nov 2, 202614d ago Press Release Neutral 2/10 Entry $10.79 Now $9.35 −13.35% settles Dec 2
  4. Oct 13, 20264w ago 144 Neutral 2/10 Entry $10.23 to $10.01 Now $9.35 −8.60% ▼ −2.15% +1.46% vs SPY
  5. Oct 2, 20266w ago Press Release Neutral 4/10 Entry $12.44 to $10.53 Now $9.35 −24.84% ▼ −15.35% −13.55% vs SPY
  6. Aug 13, 202613w ago 8-K Mixed 6/10 No price data
  7. Aug 13, 202613w ago Press Release Mixed 6/10 Entry $11.00 to $12.00 Now $9.35 −15.00% ▲ +9.09% +10.84% vs SPY
  8. Aug 6, 202614w ago Press Release Bullish 6/10 Entry $11.00 to $11.23 Now $9.35 −15.00% ▲ +2.09% +1.49% vs SPY
  9. May 28, 202624w ago Press Release Neutral 4/10 Entry $12.20 to $11.64 Now $9.35 −23.36% ▼ −4.59% −1.45% vs SPY
  10. May 20, 202625w ago Press Release Neutral 4/10 Entry $10.72 to $12.14 Now $9.35 −12.78% ▲ +13.25% +12.51% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens Wed (10h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 31, 2026